Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1;11(4):784.
doi: 10.3390/vaccines11040784.

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity

Jinnam Kim  1   2   3 , Changhyup Kim  1   2 , Jung Ah Lee  1   2 , Se Ju Lee  1   2 , Ki Hyun Lee  1   2 , Jung Ho Kim  1   2 , Jin Young Ahn  1   2 , Su Jin Jeong  1   2 , Nam Su Ku  1   2 , Joon-Sup Yeom  1   2 , Young Goo Song  1   2 , Jun Yong Choi  1   2
Affiliations

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity

Jinnam Kim et al. Vaccines (Basel). .

Abstract

This study investigated the immunogenicity of, and reactogenicity to, the ChAdOx1 nCoV-19 vaccine according to pre-existing adenovirus immunity. Individuals scheduled for COVID-19 vaccination were prospectively enrolled in a tertiary hospital with 2400 beds from March 2020 onwards. Pre-existing adenovirus immunity data was obtained before ChAdOx1 nCoV-19 vaccination. A total of 68 adult patients administered two doses of the ChAdOx1 nCoV-19 vaccine were enrolled. Pre-existing adenovirus immunity was identified in 49 patients (72.1%), but not in the remaining 19 patients (27.9%). The geometric mean titer of S-specific IgG antibodies was statistically higher in individuals without pre-existing adenovirus immunity at several time points: before the second ChAdOx1 nCoV-19 dose (56.4 (36.6-125.0) vs. 51.0 (17.9-122.3), p = 0.024), 2-3 weeks after the second ChAdOx1 nCoV-19 dose (629.5 (451.5-926.5) vs. 555.0 (287.3-926.0), p = 0.049), and 3 months after the second ChAdOx1 nCoV-19 dose (274.5 (160.5-655.3) vs. 176.0 (94.3-255.3), p = 0.033). In the absence of pre-existing adenovirus immunity, systemic events were observed with higher frequency, especially chills (73.7% vs. 31.9%, p = 0.002). In conclusion, individuals without pre-existing adenovirus immunity showed a higher immune response to ChAdOx1 nCoV-19 vaccination and a higher frequency of reactogenicity to ChAdOx1 nCoV-19 vaccination was observed.

Keywords: ChAdOx1 nCoV-19; adenoviridae; adenovirus vaccines; immunogenicity; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
(a) Flow chart of individuals with ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; (b) Timetable of individuals with ChAdOx1 nCoV-19 vaccination.
Figure 1
Figure 1
(a) Flow chart of individuals with ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; (b) Timetable of individuals with ChAdOx1 nCoV-19 vaccination.
Figure 2
Figure 2
(a) Spike (S)-specific IgG titers after ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; (b) Plaque reduction neutralization test (PRNT50) data after ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; *, p < 0.05.
Figure 2
Figure 2
(a) Spike (S)-specific IgG titers after ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; (b) Plaque reduction neutralization test (PRNT50) data after ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity; *, p < 0.05.
Figure 3
Figure 3
Reactogenicity to ChAdOx1 nCoV-19 vaccination according to pre-existing adenovirus immunity.
See this image and copyright information in PMC

References

    1. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893. doi: 10.1016/S0140-6736(08)61591-3. - DOI - PMC - PubMed
    1. Kreppel F., Hagedorn C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. Int. J. Mol. Sci. 2021;22:2417. doi: 10.3390/ijms22052417. - DOI - PMC - PubMed
    1. Zaiss A.K., Machado H.B., Herschman H.R. The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell. Biochem. 2009;108:778–790. doi: 10.1002/jcb.22328. - DOI - PMC - PubMed
    1. Lynch J.P., 3rd, Fishbein M., Echavarria M. Adenovirus. Semin. Respir. Crit. Care Med. 2011;32:494–511. doi: 10.1055/s-0031-1283287. - DOI - PubMed
    1. Harro C.D., Robertson M.N., Lally M.A., O’Neill L.D., Edupuganti S., Goepfert P.A., Mulligan M.J., Priddy F.H., Dubey S.A., Kierstead L.S., et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res. Hum. Retrovir. 2009;25:103–114. doi: 10.1089/aid.2008.0212. - DOI - PMC - PubMed

LinkOut - more resources